Literature DB >> 21577322

Prognostic significance of NQO1 expression in intrahepatic cholangiocarcinoma.

Toshifumi Wakai1, Yoshio Shirai, Jun Sakata, Yasunobu Matsuda, Pavel V Korita, Masaaki Takamura, Yoichi Ajioka, Katsuyoshi Hatakeyama.   

Abstract

This study aimed to evaluate the association between the immunohistochemical expression of NAD(P) H:quinone oxidoreductase-1 (NQO1) and nuclear factor erythroid 2-related factor 2 (Nrf2) in resected specimens of intrahepatic cholangiocarcinoma (ICC) and to elucidate the prognostic value of NQO1 and Nrf2 expression. A retrospective analysis was conducted of 34 consecutive patients who underwent surgical resection for ICC. Immunohistochemistry of the resected specimens was conducted using each of the following primary monoclonal antibodies against NQO1 and Nrf2. Of the 34 patients, 23 were classified as having tumors with NQO1-positive expression and 11 had tumors with loss of NQO1 expression, whereas 22 patients had tumors with Nrf2-positive expression and 12 had tumors with loss of Nrf2 expression. NQO1 expression showed a positive association with Nrf2 expression (p=0.005). Loss of NQO1 expression was more frequent in tumor specimens that were moderately or poorly differentiated (11/26; 42%) than in well-differentiated tumors (0/8; 0%; p=0.034). Post-resection survival was significantly worse in patients with tumors with loss of NQO1 expression than in patients with NQO1-positive tumors (cumulative 5 -year survival rate of 0% and 51%, respectively; p=0.005). Nrf2 expression was not associated with survival after resection (p=0.287). The Cox proportional hazards regression analysis revealed that lymph node involvement (p<0.001) and loss of NQO1 expression (p<0.001) had an independent adverse effect on survival. Loss of NQO1 expression reflects dedifferentiation and thus indicates a poor prognosis for patients undergoing resection for ICC.

Entities:  

Keywords:  NAD (P)H:quinone oxidoreductase-1 (NQO1); intrahepatic cholangiocarcinoma; nuclear factor erythroid 2-related factor 2 (Nrf2); prognosis; surgical resection

Mesh:

Substances:

Year:  2011        PMID: 21577322      PMCID: PMC3093061     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  26 in total

1.  Subcellular localization of NAD(P)H:quinone oxidoreductase 1 in human cancer cells.

Authors:  Shannon L Winski; Yiannis Koutalos; David L Bentley; David Ross
Journal:  Cancer Res       Date:  2002-03-01       Impact factor: 12.701

2.  Significance of genetic variation at the glutathione S-transferase M1 and NAD(P)H:quinone oxidoreductase 1 detoxification genes in breast cancer development.

Authors:  Nava Siegelmann-Danieli; Kenneth H Buetow
Journal:  Oncology       Date:  2002       Impact factor: 2.935

3.  NQO1 stabilizes p53 through a distinct pathway.

Authors:  Gad Asher; Joseph Lotem; Rachel Kama; Leo Sachs; Yosef Shaul
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-26       Impact factor: 11.205

Review 4.  Regulation of genes encoding NAD(P)H:quinone oxidoreductases.

Authors:  A K Jaiswal
Journal:  Free Radic Biol Med       Date:  2000-08       Impact factor: 7.376

5.  Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1.

Authors:  D Siegel; A Anwar; S L Winski; J K Kepa; K L Zolman; D Ross
Journal:  Mol Pharmacol       Date:  2001-02       Impact factor: 4.436

6.  High levels of expression of the NAD(P)H:quinone oxidoreductase (NQO1) gene in tumor cells compared to normal cells of the same origin.

Authors:  T Cresteil; A K Jaiswal
Journal:  Biochem Pharmacol       Date:  1991-08-08       Impact factor: 5.858

7.  Breast cancer: role of polymorphisms in biotransformation enzymes.

Authors:  Jana Sarmanová; Simona Sůsová; Ivan Gut; Marcela Mrhalová; Roman Kodet; Jan Adámek; Zdenek Roth; Pavel Soucek
Journal:  Eur J Hum Genet       Date:  2004-10       Impact factor: 4.246

8.  Immunohistochemical analysis of NAD(P)H:quinone oxidoreductase and NADPH cytochrome P450 reductase in human superficial bladder tumours: relationship between tumour enzymology and clinical outcome following intravesical mitomycin C therapy.

Authors:  Saurajyoti Basu; John E Brown; G Michael Flannigan; Jason H Gill; Paul M Loadman; Sandie W Martin; Brian Naylor; Andrew J Scally; Jill M Seargent; Tariq Shah; Rajiv Puri; Roger M Phillips
Journal:  Int J Cancer       Date:  2004-05-01       Impact factor: 7.396

9.  Cytosolic NAD(P)H:(quinone-acceptor)oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol.

Authors:  J J Schlager; G Powis
Journal:  Int J Cancer       Date:  1990-03-15       Impact factor: 7.396

10.  Interaction of human NAD(P)H:quinone oxidoreductase 1 (NQO1) with the tumor suppressor protein p53 in cells and cell-free systems.

Authors:  Adil Anwar; Donna Dehn; David Siegel; Jadwiga K Kepa; Luo Jia Tang; Jennifer A Pietenpol; David Ross
Journal:  J Biol Chem       Date:  2003-01-14       Impact factor: 5.157

View more
  7 in total

1.  Downregulation of NAD(P)H:quinone oxidoreductase 1 inhibits proliferation, cell cycle and migration of cholangiocarcinoma cells.

Authors:  Siriwoot Butsri; Veerapol Kukongviriyapan; Laddawan Senggunprai; Sarinya Kongpetch; Ponsilp Zeekpudsa; Auemduan Prawan
Journal:  Oncol Lett       Date:  2017-03-29       Impact factor: 2.967

Review 2.  Review to better understand the macroscopic subtypes and histogenesis of intrahepatic cholangiocarcinoma.

Authors:  Yuichi Sanada; Yujo Kawashita; Satomi Okada; Takashi Azuma; Shigetoshi Matsuo
Journal:  World J Gastrointest Pathophysiol       Date:  2014-08-15

3.  Adjuvant treatment in biliary tract cancer: to treat or not to treat?

Authors:  Stefano Cereda; Carmen Belli; Michele Reni
Journal:  World J Gastroenterol       Date:  2012-06-07       Impact factor: 5.742

4.  The expression and clinicopathological role of CDX2 in intrahepatic cholangiocarcinoma.

Authors:  Haowen Tang; Zhanbo Wang; Wenping Lv; Xuan Meng
Journal:  Intractable Rare Dis Res       Date:  2018-05

5.  Predictors for the development of cholangiocarcinoma and hepatocellular carcinoma: in search for the most accurate biomarker.

Authors:  Alexandros A Tzovaras; Konstantinos Kamposioras; Alexandros Ardavanis
Journal:  Arch Med Sci       Date:  2011-12-30       Impact factor: 3.318

6.  Clinical implications of high NQO1 expression in breast cancers.

Authors:  Yang Yang; Yan Zhang; Qunying Wu; Xuelian Cui; Zhenhua Lin; Shuangping Liu; Liyan Chen
Journal:  J Exp Clin Cancer Res       Date:  2014-02-05

7.  Correlation of NQO1 and Nrf2 in Female Genital Tract Cancer and Their Precancerous Lesions (Cervix, Endometrium and Ovary).

Authors:  Nisreen Abdel Tawab Abdel Gaber Osman; Nehad M R Abd El-Maqsoud; Saad Abdelnaby A El Gelany
Journal:  World J Oncol       Date:  2015-06-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.